New Delhi Jan 26: US-based drug firm Gilead Sciences Inc. has expanded its hepatitis C generic licensing agreements with India-based firms to include investigational pan-genotypic medicine GS-5816 as part of a single tablet regimen that combines it and sofosbuvir. The investigational NS5A inhibitor GS-5816 is being evaluated in Phase III clinical studies as part of a single tablet regimen that combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis C Gilead Sciences Inc said in a statement today. The expanded agreements will allow Gilead's India-based partners to manufacture GS-5816 and the single tablet regimen of
